Galapagos Obtains U.S. Patent Protecting Its Discovery Platform
News Oct 07, 2005
Galapagos has announced that it has received a Notice of Allowance of a third US patent related to “High throughput screening of gene function using adenoviral libraries for functional genomics applications.”
Whereas the first two granted US patents claimed the adenoviral library and the method of producing such library, this third patent protects the method of determining the function of a nucleic acid; moreover, it extends the patent life until 2019.
In 2004, the European patent office granted Galapagos a patent with similar claims that remained unchallenged during the opposition period, and in May 2005 Galapagos was granted the corresponding Japanese patent.
This suite of granted patents protects the Company's adenoviral gene knock-down (SilenceSelect®) and gene knock-in (FLeXSelect®) collections, the core of multiple target discovery deals with pharmaceutical and biotech companies as well as patient organizations.
"We are very pleased with this latest Notice of Allowance, as it strengthens the protection of our technologies in functional genomics services into the next decade," said Onno van de Stolpe, CEO of Galapagos.
"It also underscores our strategy to systematically protect inventions made by our innovative scientific teams."
"Our intellectual property position provides us with a unique position in drug target discovery and this translates into income to support our internal drug discovery efforts."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018